Antisense Oligonucleotides Reverse Rare Neurodevelopmental Disorder In Preclinical Models

Apr 22 2026

Scientists astatine St. Jude Children's Research Hospital person recovered they tin reverse nan effects of HNRNPH2-related neurodevelopmental upset utilizing antisense oligonucleotides (ASOs) successful preclinical models. ASOs are short synthetic nucleic acerb strands that target circumstantial messenger RNA. Published in Science Translational Medicine, nan researchers showed that ASOs artifact accumulation of nan aberrant HNRNPH2 protein. This result boosts look of nan intimately related HNRNPH1 protein, reducing aggregate symptoms of nan disorder. The activity provides captious mechanistic information to support nan advancement of this promising therapy to objective studies.

HNRNPH2-related neurodevelopmental upset is an X-linked familial information whose symptoms see developmental delay, seizures, and problems pinch movement, learning and memory. Fewer than 200 cases person been confirmed to date, classifying it arsenic ultrarare. There is presently nary cure for HNRNPH2-related neurodevelopmental disorder, successful portion because nan rarity of this information presents an obstacle to some investigation and therapeutic investment.

"Since HNRNPH2-related upset was first identified successful patients a decade ago, we person worked to amended understand nan mechanisms driving nan disease. It was a singular convergence that we discovered its molecular ground conscionable arsenic ASOs were emerging arsenic an effective therapeutic technology. The system we identified was particularly good suited to an ASO-based approach, allowing america to intervene straight astatine nan root of nan disease," said corresponding author J. Paul Taylor, MD, PhD, St. Jude executive vice president, technological director, Department of Cell & Molecular Biology chair and Pediatric Translational Neuroscience Initiative director. "This study represents nan adjacent measurement successful bringing existent alleviation to patients and families for whom curen options are presently nonexistent."

ASO therapy kicks retired HNRNPH2, boosts HNRNPH1

Rather than altering nan mutated cistron itself, ASO therapies target nan messenger RNA produced from that gene. The ASOs targeting HNRNPH2 flag its RNA for demolition earlier an aberrant macromolecule tin beryllium made. Previous studies from Taylor's lab have shown that reducing HNRNPH2 macromolecule levels encourages nan intimately related protein, HNRNPH1, to measurement up to compensate.

Both proteins are captious to RNA processing and apt play overlapping roles during development. Notably, whereas HNRNPH1 expression decreases arsenic improvement proceeds, HNRNPH2 expression persists until cells go progressively much limited connected it. However, nan system underlying this developmental modulation and really HNRNPH2 influences HNRNPH1 expression remained unclear. Further, nan researchers were unsure whether HNRNPH2mutations made nan resulting macromolecule activity abnormally (gain of function) aliases not astatine each (loss of function).

In this study, nan researchers recovered that HNRNPH2 regulates HNRNPH1 expression by promoting cistron look systems to skip a captious portion of nan gene. This skip causes immoderate resulting HNRNPH1 messenger RNA to beryllium promptly scrapped. The investigation showed that by silencing nan mutated HNRNPH2 with an ASO, this skip could beryllium reversed, starring to increased HNRNPH1 expression and improved symptoms.

"We hypothesized that an ASO strategy that substantially knocks down HNRNPH2 levels and increases HNRNPH1expression should beryllium effective for some gain-of-function and loss-of-function mechanisms and amended symptoms successful the HNRNPH2 preclinical models," said first writer Ané Korff, PhD, St. Jude Department of Cell & Molecular Biology. "This study tests that idea."

"We recovered that galore symptoms were reversed aft neonatal curen pinch an ASO successful nan preclinical models and besides verified this effect aft curen successful somewhat older juveniles," Korff added. Since familial diagnoses for HNRNPH2-related upset whitethorn return respective years, this consequence implies that ASO therapy whitethorn beryllium beneficial moreover later successful life.

These findings supply preclinical grounds that an ASO strategy whitethorn beryllium transformative for HNRNPH2-related neurodevelopmental upset and nan ultrarare illness organization astatine large. "The first cases of this upset were reported successful 2016, and wrong 10 years, we went from basal biology to designing a translational therapy pinch nan imaginable for existent diligent impact," said co-author Hong Joo Kim, PhD, St. Jude Department of Cell & Molecular Biology. "This is an astonishing development, and it's meaningful that nan activity is quickly moving to thief patients."